What to Expect in Your First Month on a GLP-1 Medication

The first month on a GLP-1 medication is mostly a tolerance-building phase, not a results phase. Each product starts at a low dose and follows its own escalation schedule: Zepbound starts at 2.5 mg injected once weekly for 4 weeks ^[1], Wegovy injection starts at 0.25 mg once weekly for 4 weeks ^[2], the Wegovy tablet starts at 1.5 mg once daily for 30 days ^[2], and the once-daily pill Foundayo (orforglipron) starts at 0.8 mg ^[3]. Those starting doses sit far below the maintenance doses listed in the same labels — Wegovy injection’s usual maintenance dose of 2.4 mg weekly is nearly ten times its 0.25 mg starting dose ^[2] — and each label holds the starting dose for a set interval before any increase.

What that means in practice: the first month is dominated by learning the routine (a weekly injection or a daily pill with its own rules) and noticing gastrointestinal side effects if they appear. The labels state their escalation intervals as minimums — “after at least 4 weeks” for Zepbound, “after at least 30 days” for Foundayo — and tie maintenance-dose selection to treatment response and tolerability ^{[1] [3]}. No first-month weight-loss figure has been published in any of these product labels or in the American Diabetes Association’s 2026 Standards of Care ^{[1] [2] [6]}, so any specific “expect X pounds in month one” claim you see elsewhere is not coming from the official prescribing information. Everything below is drawn from FDA prescribing information and published guideline or review literature, not personal medical advice; dosing decisions belong with the prescriber.

What dose am I actually on during the first month?

Each product has its own escalation schedule, and the schedules are not interchangeable. The table below shows what each FDA label states for the starting dose, the first step up, and the maintenance or maximum dose.

Product	Starting dose	First increase	Maintenance or maximum dose stated in the label
Zepbound (tirzepatide injection)	2.5 mg once weekly for 4 weeks [1]	In 2.5 mg increments after at least 4 weeks [1]	5 mg, 10 mg, or 15 mg once weekly (weight); 10 mg or 15 mg for OSA [1]
Wegovy injection (semaglutide)	0.25 mg once weekly for 4 weeks [2]	Titrate every 4 weeks per the label’s schedule [2]	Usual maintenance 2.4 mg once weekly [2]
Wegovy tablets (semaglutide)	1.5 mg once daily for 30 days [2]	Titrate every 30 days [2]	25 mg once daily [2]
Ozempic (semaglutide injection, type 2 diabetes)	0.25 mg once weekly [8]	0.5 mg once weekly after 4 weeks [8]	1 mg or 2 mg once weekly if more glycemic control is needed [8]
Foundayo (orforglipron tablets)	0.8 mg once daily [3]	2.5 mg once daily after at least 30 days [3]	Escalation steps of 9 mg, 14.5 mg, or 17.2 mg once daily; maximum dosage 17.2 mg once daily [3]
Saxenda (liraglutide injection)	0.6 mg per day for one week [4]	Increase at weekly intervals [4]	Recommended dose 3 mg daily [4]

A few details from the labels are worth noticing. Zepbound’s label says to increase in 2.5 mg increments only after at least 4 weeks on the current dosage, and to consider treatment response and tolerability when selecting the maintenance dosage ^[1]. Foundayo’s label follows the same logic on a daily-pill timeline: 0.8 mg once daily, then 2.5 mg after at least 30 days, then 5.5 mg after at least 30 days on 2.5 mg, with further increases to 9 mg, 14.5 mg, or 17.2 mg at 30-day intervals based on response and tolerability, up to a maximum of 17.2 mg ^[3]. Saxenda, a daily injection, escalates at weekly intervals: 0.6 mg per day for one week, then weekly increases until 3 mg ^[4]. For pediatric patients on Saxenda, the label notes escalation may take up to 8 weeks and that the dose may be lowered back to the previous level if an increase is not tolerated; pediatric patients not tolerating 3 mg daily may be reduced to 2.4 mg daily ^[4].

All of these drugs are indicated only in combination with a reduced-calorie diet and increased physical activity ^{[1] [2] [3]} — the medication is one part of the plan, not a substitute for it.

Why do you start on such a low dose of Ozempic or Wegovy?

Because the FDA prescribing information for each product specifies a starting dose held for a set interval before any increase. The Ozempic label (type 2 diabetes indication) starts at 0.25 mg once weekly, increases to 0.5 mg after 4 weeks, and then to 1 mg and 2 mg only after at least 4 weeks on each prior dosage, and only if more glycemic control is needed ^[8]. The Zepbound label starts at 2.5 mg once weekly for 4 weeks and permits increases in 2.5 mg increments only after at least 4 weeks on the current dosage ^[1]. The Wegovy injection label uses the same structure: initiate at 0.25 mg once weekly for 4 weeks, then titrate every 4 weeks toward maintenance ^[2]. The Foundayo label states its 30-day minimums explicitly, tying each increase to treatment response and tolerability ^[3].

What the labels also state is that gastrointestinal adverse reactions dominate the common-adverse-reaction lists, and that use has been associated with gastrointestinal adverse reactions, sometimes severe ^{[1] [3] [4]}. Zepbound, Foundayo, and Saxenda all carry statements that they are not recommended in patients with severe gastroparesis ^{[1] [3] [4]}. The escalation intervals are written as minimums (“after at least 4 weeks” for Zepbound, “after at least 30 days” for Foundayo), not as commands to increase on a fixed clock ^{[1] [3]}.

What side effects are common in the first weeks?

The labels list the adverse reactions reported in 5% or more of treated patients, and the lists are dominated by digestive symptoms. For Zepbound: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease ^[1]. For Foundayo: nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss ^[3]. For Saxenda: nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis ^[4].

Two first-month cautions appear across the labels. First, dehydration: Zepbound, Foundayo, and Saxenda all carry a warning about acute kidney injury due to volume depletion, instructing clinicians to monitor renal function in patients reporting adverse reactions that could lead to volume depletion ^{[1] [3] [4]}; the Wegovy label lists an Acute Kidney Injury due to Volume Depletion warning section among its recent changes ^[2]. Either way, vomiting or diarrhea severe enough to drop fluid intake is a medical issue, not just an annoyance. Second, Saxenda specifically carries a heart-rate warning: monitor heart rate at regular intervals ^[4].

How much weight do people lose in the first month?

No first-month weight-loss figure appears in any of these product labels or in the ADA’s 2026 Standards of Care ^{[1] [2] [6]}. The prescribing information does not promise a number for week four, and neither does the guideline document — so there is no official benchmark to measure yourself against after 30 days.

What the ADA Standards of Care 2026 does say is about longer horizons: weight loss of 5–7% of baseline weight improves glycemia and other intermediate cardiovascular risk factors, and sustained loss of more than 10% of body weight usually confers greater benefits, including disease-modifying effects and possible remission of type 2 diabetes ^[6]. The same document recommends aiming for any magnitude of weight loss when providing weight management treatment ^[6], and recommends increasing anthropometric monitoring to at least every 3 months during active weight management treatment ^[6] — a quarterly checkpoint, not a weekly one.

Do I have to move up to the next dose at week 4?

That is a prescriber decision, and the labels are written to make it one. Zepbound’s label says to consider treatment response and tolerability when selecting the maintenance dosage ^[1], and its escalation interval is a minimum — “after at least 4 weeks” — not a mandate to increase on day 29 ^[1]. Foundayo’s label uses the same structure with 30-day minimums and explicitly bases increases on treatment response and tolerability ^[3]. The ADA Standards of Care 2026 recommends individualizing initial treatment approaches based on the person’s medical history, life circumstances, and preferences ^[6].

The Saxenda pediatric language shows the flexibility the FDA allows in this class: if a pediatric patient does not tolerate an increased dose during escalation, the label states the dose may be lowered to the previous level ^[4].

What happens if I miss a weekly injection?

Only one missed-dose rule is supported in the label material here, and it is product-specific: the Ozempic injection label states that if a dose is missed, it should be administered within 5 days of the missed dose ^[8]. That rule does not transfer to other products. Each product’s prescribing information contains its own “Recommendations Regarding Missed Dose” section — Zepbound’s is section 2.3 of its full prescribing information ^[1] — and the rules are not interchangeable. For the daily pill Foundayo, the label states simply: do not take more than one tablet per day ^[3]. For any specific missed-dose situation, the product’s own label section and the prescriber’s guidance govern; this page does not tell you what to do.

Do the pills have different rules than the injections?

Yes, and the differences start on day one. The Wegovy tablet label spells out a detailed routine: take once daily on an empty stomach in the morning with water only — up to 4 ounces — no other liquids, swallow whole (do not split, crush, chew, or dissolve), and then wait at least 30 minutes before eating food, drinking beverages, or taking other oral medications ^[2]. Foundayo’s label is less restrictive: take once daily with or without food, swallow whole, do not break, crush, or chew, and do not take more than one tablet per day ^[3].

The injections have their own logistics. Wegovy injection is given once weekly on the same day each week, at any time of day, with or without meals, injected subcutaneously in the abdomen, thigh, or upper arm ^[2]; Saxenda is injected once daily at any time, without regard to meal timing, in the same three sites ^[4]. One rule the labels added recently applies to the multi-dose pens: never share a Zepbound KwikPen between patients, even if the pen needle is changed (a warning added 01/2026) ^[1]; never share a Wegovy FlexTouch pen between patients (added 06/2026) ^[2]; and never share an Ozempic pen between patients, even if the needle is changed ^[8].

Drug interactions also differ. Foundayo’s label caps the dosage at 9 mg once daily when used with a strong CYP3A4 inhibitor, says to avoid strong CYP3A4 inhibitors that also inhibit OATP1B, avoid strong CYP3A4 inducers, and not to exceed simvastatin 20 mg daily when taken together ^[3]. More broadly, Zepbound, Foundayo, and Saxenda all state they delay gastric emptying and may impact the absorption of other oral medications ^{[1] [3] [4]}. And none of these products should be combined: coadministration with another GLP-1 receptor agonist, or another product containing the same drug, is not recommended across Zepbound, Wegovy, Foundayo, and Saxenda ^{[1] [2] [3] [4]}.

For people with diabetes, the Wegovy label says to monitor blood glucose prior to starting and during treatment ^[2], and the Saxenda label says adults with type 2 diabetes should do the same ^[4].

Do I need backup birth control after starting?

The labels say yes for two products, with slightly different windows. The Zepbound label advises females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation ^[1]. The Foundayo label gives the same advice with 30-day windows: for 30 days after initiation and for 30 days after each dose escalation ^[3]. Both labels also state the drugs may cause fetal harm and should be discontinued when pregnancy is recognized ^{[1] [3]}.

When should I call a doctor during the first month rather than waiting it out?

The labels list specific events that warrant prompt medical attention, and they apply from the first dose onward:

• Severe digestive symptoms or dehydration. Beyond the sometimes-severe GI warning ^{[1] [3] [4]}, the volume-depletion/kidney-injury warnings tell clinicians to monitor renal function in patients reporting reactions that could lead to volume depletion ^{[1] [3] [4]}, and the Wegovy label carries the same warning section ^[2].
• Possible pancreatitis. Acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists; the Zepbound, Foundayo, and Saxenda labels all say to discontinue if pancreatitis is suspected ^{[1] [3] [4]}.
• Possible gallbladder problems. Acute gallbladder disease has been reported in clinical trials. The Zepbound and Foundayo labels say that if cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated ^{[1] [3]}; the Saxenda label says gallbladder studies are indicated if cholelithiasis or cholecystitis is suspected ^[4].
• Allergic reactions. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported; the labels say to seek medical attention promptly and discontinue the drug ^{[1] [3] [4]}.
• Low blood sugar (for people on insulin or a sulfonylurea). Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia, and reducing the dose of those other medications may be necessary ^{[1] [3] [4]}.
• Thyroid-tumor symptoms. The Zepbound boxed warning lists symptoms to report: a mass in the neck, dysphagia, dyspnea, or persistent hoarseness ^[1]. Zepbound, Wegovy, Foundayo, and Saxenda are all contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 ^{[1] [2] [3] [4]}.
• Planned surgery. Pulmonary aspiration during general anesthesia or deep sedation has been reported in GLP-1 users undergoing elective procedures; the labels instruct patients to tell healthcare providers about any planned surgeries or procedures ^{[1] [3] [4]}.
• Eye changes (for people with diabetic retinopathy). The Zepbound and Foundayo labels say to monitor patients with a history of retinopathy for progression ^{[1] [3]}.

What do real-world data show about staying on GLP-1s over one to two years?

Real-world data suggest staying on these medications is a common struggle, though the published numbers cover six months to two years, not month one specifically. A narrative review published August 15, 2026 in Current Diabetes Reports examined seven studies of adults with obesity and type 2 diabetes, with follow-up ranging from 6 months to 2 years ^[5]. Persistence generally declined over time and often fell below 60% by 12 to 24 months, though estimates varied by how a refill gap was defined ^[5]. In one large cohort, discontinuation reached 64.1% at 2 years, and treatment interruption followed by reinitiation was common ^[5].

The same review found persistence varied by age, income, gastrointestinal adverse events, weight reduction, BMI-related measures, which GLP-1 agent was used, formulation, and dosing schedule ^[5]. Only two of the seven studies reported patient-level reasons for stopping, and the most common reason was adverse effects; none of the studies described structured behavioral or supportive strategies ^[5]. The review also notes discontinuation has been associated with weight regain and loss of metabolic benefit, and that regain after stopping may occur more rapidly than after behavioral weight-management programs ^[5].

Which label versions do these facts come from?

The Zepbound prescribing information was revised 8/2026; its recent changes include the Severe Gastrointestinal Adverse Reactions warning (02/2026), the never-share-KwikPen warning (01/2026), and removal of the Suicidal Behavior and Ideation section (02/2026) ^[1]. The Wegovy label was updated June 18, 2026, and also removed its Suicidal Behavior and Ideation section in 02/2026 ^[2]. Foundayo, whose initial U.S. approval was 2026, was revised 7/2026 ^[3]. The Saxenda label was updated February 25, 2026, with the Suicidal Behavior and Ideation section removed in 02/2026 ^[4]. The Ozempic injection label was updated June 1, 2026 ^[8].

Sources

1. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Prescribing information. Initial U.S. approval: 2022.
2. National Library of Medicine, DailyMed. WEGOVY (semaglutide) injection, solution. Drug label.
3. National Library of Medicine, DailyMed. FOUNDAYO (orforglipron) tablet, film coated. Drug label.
4. National Library of Medicine, DailyMed. SAXENDA (liraglutide) injection, solution. Drug label.
5. PubMed Central. Persistence in GLP-1-Based Therapy Among Adults with Obesity and Type 2 Diabetes: A Narrative Review of Definitions, Real-World Outcomes, and Determinants.
6. PubMed Central. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026.
7. Reddit. Zepbound community discussion thread on personal experience with tirzepatide injections.
8. National Library of Medicine, DailyMed. OZEMPIC (semaglutide) injection, solution. Drug label.
9. PubMed Central. After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care.
10. National Library of Medicine, DailyMed. RYBELSUS (oral semaglutide) tablet. Drug label.
11. National Library of Medicine, DailyMed. TRULICITY (dulaglutide) injection, solution. Drug label.